A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers

PHASE2TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

July 5, 2018

Primary Completion Date

January 16, 2020

Study Completion Date

January 16, 2020

Conditions
Relapsed or Refractory Multiple Myeloma
Interventions
DRUG

Dexamethasone

Dexamethasone will be taken orally or by IV infusion at a dose of 20 mg once-daily on days 1, 2, 8, 9, 15, 16, 22, and 23 of cycles 1-6, and at a dose 40 mg once-daily on days 1, 8, 15 of cycles 7-12.

DRUG

Carfilzomib

Carfilzomib will be administered at 20 mg/m² on days 1 and 2 of the first cycle. After that, carfilzomib will be administered at 56 mg/m² on days 8, 9, 15, and 16 of the first cycle, and then on days 1, 2, 8, 9, 15, and 16 on each 28-day cycle for the cycles 2 through 6. Starting with cycle 7 through cycle 12, carfilzomib will be administered at 70 mg/m² on days 1, 8, and 15 of each 28-day cycle. All

Trial Locations (31)

20817

Research Site, Bethesda

22408

Research Site, Fredericksburg

27103

Research Site, Winston-Salem

28204

Research Site, Charlotte

28207

Research Site, Charlotte

28374

Research Site, Pinehurst

28792

Research Site, Hendersonville

29414

Research Site, Charleston

29732

Research Site, Rock Hill

32504

Research Site, Pensacola

32763

Research Site, Orange City

33426

Research Site, Boynton Beach

39202

Research Site, Jackson

42003

Research Site, Paducah

43701

Research Site, Zanesville

46260

Research Site, Indianapolis

48640

Research Site, Midland

60305

Research Site, River Forest

60487

Research Site, Tinley Park

68506

Research Site, Lincoln

76104

Research Site, Fort Worth

77057

Research Site, Houston

77090

Research Site, Houston

78412

Research Site, Corpus Christi

81601

Research Site, Glenwood Springs

84405

Research Site, Ogden

92262

Research Site, Palm Springs

92501

Research Site, Riverside

96813

Research Site, Honolulu

98902

Research Site, Yakima

07932

Research Site, Florham Park

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY

NCT03512353 - A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers | Biotech Hunter | Biotech Hunter